Chewy, Inc. — Form 10-K Summary
Period and scope: This filing covers fiscal year 2023, the 52 weeks ended January 28, 2024, with comparisons to fiscal 2022 ended January 29, 2023. This does not match the request metadata “2022 Q4.” Chewy is an online retailer of pet products and services, including pharmacy and other pet-health offerings. Comparative financial statements were restated to include Chewy Pharmacy KY following a common-control transaction; this was not described as an error correction.
Financial and operating performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $11.148 billion | $10.119 billion | +10.2% |
| Gross profit / margin | $3.162 billion / 28.4% | $2.834 billion / 28.0% | Margin +40 bps |
| Operating income (loss) | $(23.6) million | $56.4 million | Declined |
| Net income | $39.6 million | $49.9 million | -20.7% |
| Net margin | 0.4% | 0.5% | -10 bps |
| Adjusted EBITDA (non-GAAP) | $368.1 million; 3.3% margin | $306.7 million; 3.0% margin | +20.0% |
| Operating cash flow / free cash flow (non-GAAP) | $486.2 million / $342.9 million | $349.8 million / $119.5 million | FCF +187.0% |
| Active customers | 20.083 million | 20.405 million | -1.6% |
| Net sales per active customer | $555 | $496 | +11.9% |
| Autoship customer sales | $8.493 billion; 76.2% of sales | $7.408 billion; 73.2% of sales | Sales +14.7% |
Revenue growth was led by consumables, up 12.2%, and “other,” up 9.4%; hardgoods declined 0.5%. Gross-margin improvement reflected gains in healthcare, hardgoods and private brands, as well as supply-chain efficiencies. Operating expenses grew faster than sales: SG&A rose 14.8% and advertising and marketing 14.3%. GAAP operating results turned to a loss, while positive net income reflected $58.5 million of net interest income and $13.4 million of other income. Share-based compensation expense was $239.1 million.
Cash and cash equivalents were $602.2 million and marketable securities were $531.8 million at year-end. Current assets were $2.104 billion versus current liabilities of $2.111 billion. The company reported no borrowings on its $800 million asset-based revolving facility and $759.0 million of borrowing capacity, subject to the borrowing base. Total liabilities were $2.677 billion; reported operating lease liabilities were $556.8 million, with $900.4 million of undiscounted minimum lease payments.
Material changes and unusual items
- Net sales growth moderated to 10.2% from 12.8% in FY2022. Active customers declined, while spending per active customer and Autoship penetration increased.
- Capital expenditures fell to $143.3 million from $230.3 million, contributing to the increase in free cash flow. Investing cash outflow also reflected $143.7 million of net purchases of marketable securities.
- In October 2023, Chewy completed a BC Partners-affiliated ownership reorganization that made Chewy Pharmacy KY an indirect wholly owned subsidiary. The filing says the comparative periods were restated to include that business. It also describes a $1.9 billion transfer from BC Partners affiliates to fund assumed tax obligations and transaction costs; Chewy paid $1.8 billion in related income taxes during the year. The filing reports a $108.9 million year-end payable on those assumed taxes and a $48.3 million receivable for tax indemnification.
- FY2023 included $14.3 million of severance costs and $6.8 million of exit costs, which management excludes from certain non-GAAP measures. Adjusted EBITDA, adjusted net income and free cash flow are non-GAAP measures and should be considered alongside GAAP results.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Vendor rebates were identified as a critical audit matter because of the complexity of agreement terms and rebate accruals.
Outlook, risks and contingencies
The filing provides no numeric revenue or earnings guidance. Management says it expects to continue investing in technology, automation, healthcare, customer acquisition and supply chain, and is pursuing expansion in Canada, CarePlus and planned Chewy Vet Care clinics. Management notes uncertainty from inflation, interest rates and broader economic conditions.
- Key execution risks include acquiring and retaining customers cost-effectively, improving margins, maintaining fulfillment and shipping performance, and delivering returns on new healthcare and international initiatives.
- Supplier concentration is notable: the three largest vendors represented approximately 39% of FY2023 net sales. Vendor rebates also affect cost of goods sold and were the critical audit matter.
- The company identifies cybersecurity, third-party technology and cloud-provider dependence, product safety, pharmacy and veterinary regulation, and changes in consumer spending as material risks. It reports occasional cyber incidents, but none had a material impact to date.
- IBM patent litigation remains unresolved: a March 2024 appellate decision upheld prior rulings except for a claim remanded for further proceedings; IBM also asserts infringement of reexamined claims of another patent. Chewy denies infringement and says it intends to defend itself. Management does not believe current legal matters will have a material adverse effect, though outcomes are uncertain.
- Chewy has a full valuation allowance on net deferred tax assets because of its loss history. The filing also describes transaction-related tax indemnification; verify the scope and limits of the applicable protections, including the stated $196 million cap for certain future tax exposure.
- BC Partners-affiliated stockholders control more than 95% of voting power as of March 13, 2024. The dual-class structure and controlled-company status limit the influence and governance protections of Class A holders.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied filing is FY2023, not FY2022 Q4.
- Review the reconciliation of non-GAAP results, particularly recurring share-based compensation and the difference between GAAP operating loss and positive adjusted EBITDA.
- Assess whether rising sales per customer and Autoship can offset continued customer-count declines, and whether newer investments can sustain margin and cash-flow gains.
- Check the details and remaining exposure of the BC Partners tax funding and indemnities, including the year-end tax payable and receivable.
- Monitor the IBM litigation, vendor concentration and rebates, and available borrowing capacity under the asset-based facility.